These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1612871)

  • 1. [Are the publicized advantages of thrombolytic treatment of myocardial infarct with recombinant t-PA (ACTILYSE) in comparison with streptokinase so decisive, that despite the high cost a general use of ACTILYSE is justified?].
    Gulba DC
    Internist (Berl); 1992 May; 33(5):364-5. PubMed ID: 1612871
    [No Abstract]   [Full Text] [Related]  

  • 2. [Actilyse (a recombinant tissue-type plasminogen activator] in the treatment of acute myocardial infarct. Comparison of the effects of Actilyse and streptokinase].
    Bastecký J; Kvasnicka J; Macek K; Malý J; Rozsíval V; Chrobák L; Gajdosová I; Skopecková H; Wasylivová V; Ettlerová E
    Vnitr Lek; 1994 May; 40(5):293-8. PubMed ID: 8023469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the use of t-PA as compared with streptokinase cost effective?
    Armentano R; Favaloro RG
    N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905
    [No Abstract]   [Full Text] [Related]  

  • 4. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA
    N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early patency in acute myocardial infarction.
    Belenkie I
    Can J Cardiol; 1993 Mar; 9(2):149-51. PubMed ID: 8490781
    [No Abstract]   [Full Text] [Related]  

  • 11. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients].
    Machecourt J; Cassagnes J; Bassand JP; Dumoulin J; Calop J; Foroni L; Terrisse MP; Hénon T; Petit L; Denis B
    Arch Mal Coeur Vaiss; 1993 Feb; 86(2):209-17. PubMed ID: 8363422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the clinical laboratory in monitoring fibrinolytic therapy of acute myocardial infarction.
    Bovill E; Triplett D; Stump D
    Hematol Pathol; 1990; 4(2):61-6. PubMed ID: 2115512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
    Cannas S; De Leo A; Marzari A
    G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombolysis, Actilyse, myocardial infarct].
    Mezard-Eurin M
    Rev Infirm; 1988 Sep; 38(14):50-3. PubMed ID: 3143144
    [No Abstract]   [Full Text] [Related]  

  • 19. Myocardial infarction, thrombolytic therapy, and economics.
    Conti RC
    Clin Cardiol; 1993 Sep; 16(9):635. PubMed ID: 8242906
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thrombolytic therapy].
    de Gaetano G; Donati MB; Gensini GF; Restagno C
    Recenti Prog Med; 1993 Sep; 84(9):581-5. PubMed ID: 8210621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.